Friday, July 10, 2026
🇺🇸 FDA

Intelligence · INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,798
Companies 1,771
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,798 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Recently updated

FDA-approved

Showing page 10 of 200 · By data quality, then INN

  1. covid-19 mrna vaccine

    COMIRNATY Teva Pharma GmbH

    EMA: approved

    J07BN01

  2. crinecerfont

    CRENESSITY NEUROCRINE BIOSCIENCES INC

    ORAL FDA: approved

  3. crisantaspase

    ENRYLAZE Jazz Pharmaceuticals Ireland Limited

    EMA: approved

    L01XX02

  4. cromolyn sodium

    CROMOLYN SODIUM Blackmores Limited

    OPHTHALMIC FDA: approved

  5. cupric chloride

    CUPRIC CHLORIDE Amneal Pharma Europe Ltd

    INJECTION FDA: approved

  6. cupric sulfate

    CUPRIC SULFATE Regeneron Ireland Designated Activity Company (DAC)

    INJECTION FDA: approved

  7. cyanocobalamin

    CYANOCOBALAMIN Regeneron Ireland Designated Activity Company (DAC)

    N/A FDA: approved

  8. cyclacillin

    CYCLAPEN-W Teva Pharma GmbH

    ORAL FDA: approved

  9. cyclobenzaprine hydrochloride

    CYCLOBENZAPRINE HYDROCHLORIDE Tonix Pharmaceuticals Holding

    ORAL FDA: approved

  10. cyclophosphamide

    CYCLONEX Amdipharm Mercury (Australia) Pty Limited

    SOLUTION FDA: approved · TGA: approved · NMPA: clinical trials

  11. cycloserine

    SEROMYCIN Sana Biotechnology

    ORAL FDA: approved

  12. cyclosporine

    CYCLOSPORINE Amneal Pharma Europe Ltd

    OPHTHALMIC FDA: approved · NMPA: clinical trials

  13. cyproheptadine hydrochloride

    CYPROHEPTADINE HYDROCHLORIDE Beam Therapeutics

    ORAL FDA: approved

  14. cytarabine

    PFIZER AUSTRALIA PTY LTD Pfizer Australia Pty Ltd

    INJECTION FDA: approved · EMA: withdrawn · TGA: approved · NMPA: clinical trials

    L01BC01

  15. dabigatran etexilate

    DABIGATRAN ETEXILATE ACCORD Teva Pharma GmbH

    EMA: approved

    B01AE07

  16. dabigatran etexilate mesylate

    DABIGATRAN ETEXILATE MESYLATE Teva Pharma GmbH

    ORAL FDA: approved

  17. dactinomycin

    DACTINOMYCIN Regeneron Ireland Designated Activity Company (DAC)

    INJECTION FDA: approved

  18. dalbavancin hydrochloride

    DALBAVANCIN HYDROCHLORIDE Teva Pharma GmbH

    INTRAVENOUS FDA: approved

  19. dalfampridine

    DALFAMPRIDINE Teva Pharma GmbH

    ORAL FDA: approved

  20. danazol

    DANOCRINE Beam Therapeutics

    ORAL FDA: approved

  21. dantrolene sodium

    DANTRIUM ELITE PHARMACEUTICALS INC /NV/

    INJECTION FDA: approved

  22. dapagliflozin

    FORXIGA AstraZeneca

    ORAL FDA: approved · EMA: approved · TGA: approved · NMPA: clinical trials

    A10BK01

  23. dapsone

    DAPSOMED Amneal Pharma Europe Ltd

    TOPICAL FDA: approved · TGA: approved

  24. daptomycin

    CUBICIN MAIA Biotechnology

    INTRAVENOUS FDA: approved · EMA: approved

    J01XX09

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,798 pharmaceutical active ingredients and their marketed profiles — INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page — it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.